| 1.9 -0.01 (-0.52%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.8 | 1-year : | 3.21 |
| Resists | First : | 2.39 | Second : | 2.75 |
| Pivot price | 2.07  |
|||
| Supports | First : | 1.83 | Second : | 1.52 |
| MAs | MA(5) : | 1.91  |
MA(20) : | 2.16 |
| MA(100) : | 2.06 |
MA(250) : | 1.39 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 14.7 |
D(3) : | 14.1 |
| RSI | RSI(14): 34.7 |
|||
| 52-week | High : | 3.02 | Low : | 0.52 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CGEN ] has closed above bottom band by 27.3%. Bollinger Bands are 6.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.02 - 2.04 | 2.04 - 2.04 |
| Low: | 1.86 - 1.88 | 1.88 - 1.89 |
| Close: | 1.88 - 1.9 | 1.9 - 1.92 |
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Tue, 23 Apr 2024
Compugen (NASDAQ:CGEN) Shares Cross Above Two Hundred Day Moving Average of $1.69 - MarketBeat
Wed, 13 Mar 2024
Should You Hold Compugen Ltd (CGEN) Stock Wednesday Morning? - InvestorsObserver
Fri, 08 Mar 2024
Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26% - Simply Wall St
Thu, 07 Mar 2024
Compugen Ltd. (NASDAQ:CGEN) Q4 2023 Earnings Call Transcript - Yahoo Finance
Tue, 05 Mar 2024
Compugen: Q4 Earnings Snapshot - Houston Chronicle
Tue, 05 Mar 2024
Compugen Ltd. (CGEN) Q4 2023 Earnings Call Transcript - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 90 (M) |
| Shares Float | 85 (M) |
| Held by Insiders | 5.3 (%) |
| Held by Institutions | 14.2 (%) |
| Shares Short | 2,090 (K) |
| Shares Short P.Month | 1,830 (K) |
| EPS | -0.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.74 |
| Profit Margin | -56.1 % |
| Operating Margin | 53.7 % |
| Return on Assets (ttm) | -7.6 % |
| Return on Equity (ttm) | -26.2 % |
| Qtrly Rev. Growth | 346.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.37 |
| EBITDA (p.s.) | -0.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -36 (M) |
| Levered Free Cash Flow | -51 (M) |
| PE Ratio | -9.05 |
| PEG Ratio | 0 |
| Price to Book value | 2.56 |
| Price to Sales | 5.08 |
| Price to Cash Flow | -4.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|